LYRA (Lyra Therapeutics) Total Receivables: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LYRA Lyra Therapeutics Inc LYRA
29 GF Score
Price $0.57
GF Value $2.53
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lyra Therapeutics Total Receivables?

Lyra Therapeutics LYRA +9.09% 29 Total Receivables is $0.00 Mil as of Dec. 2025. GuruFocus rates LYRA with a GF Score™ of 29/100 and a GF Value™ of $2.53 (Possible Value Trap). The stock has 4 warning signs investors should review.

Lyra Therapeutics's Total Receivables for the quarter that ended in Dec. 2025 was $0.00 Mil.

Lyra Therapeutics Total Receivables Related Terms

Lyra Therapeutics Total Receivables Historical Data

* Premium members only.

The historical data trend for Lyra Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lyra Therapeutics Total Receivables Chart

Lyra Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Lyra Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LYRA
29GF Score
Lyra Therapeutics Inc LYRA
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lyra Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.00 Mil mean?
Lyra Therapeutics (LYRA) has a Total Receivables of $0.00 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Lyra Therapeutics and its competitors.
Is Lyra Therapeutics' Total Receivables too high?
Lyra Therapeutics' current Total Receivables is $0.00 Mil. Overall, Lyra Therapeutics has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lyra Therapeutics' Total Receivables compare to EVFM and CLSDQ?
Lyra Therapeutics' Total Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Lyra Therapeutics and its competitors. Lyra Therapeutics's current Total Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lyra Therapeutics (LYRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.53, compared to a current price of $0.57 — trading 77.5% below its estimated fair value. The current Total Receivables is $0.00 Mil. Lyra Therapeutics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Lyra Therapeutics (LYRA), the current Total Receivables is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lyra Therapeutics (LYRA) Overvalued in 2026?

Based on GuruFocus' analysis, Lyra Therapeutics stock appears to be undervalued. The current stock price of $0.57 is trading 77.5% below its estimated GF Value™ of $2.53. GuruFocus considers Lyra Therapeutics to be Possible Value Trap.

Key valuation signals for LYRA:

  • Total Receivables: $0.00 Mil
  • GF Value™: $2.53 vs. price of $0.57 (77.5% below fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the LYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyra Therapeutics Business Description

Address 480 Arsenal Way, Watertown, MA, USA, 02472
Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases.
29GF Score

Get the complete analysis for LYRA

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price
$2.53
GF Value